AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00308724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: 8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
Study NCT00308724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone check-in
Description: Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
Study NCT00783367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;
Study NCT00783367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
Study NCT02664961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
Study NCT01207466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A investigational contact lens
Description: Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
Study NCT01207466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A commercial contact lens
Description: Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
Study NCT02664961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be dosed every two weeks.
Study NCT02310373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine free hookah smoking
Description: Subjects will smoke waterpipe in a controlled research environment
Study NCT00095563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT02444715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
Study NCT02444715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPSYS
Description: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
Study NCT02067624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage
Study NCT02067624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study NCT00095563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01661322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, Dipyradimole, Clopidogrel
Description: Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
Study NCT01517035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
Study NCT05163704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
Study NCT01696357 — intervention group
Intervention type: DEVICE
Intervention: Automated Device for Asthma Monitoring (ADAM)
Description: Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
Study NCT01804803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.
Description: Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS).
Study NCT01804803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of regular glucometer
Study NCT00938951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® Ultra
Description: Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
Study NCT02865850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02865850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study NCT05178095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence
Description: Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
Study NCT05178095 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Artificial Intelligence
Description: Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
Study NCT02722044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Study NCT02722044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Subcutaneous administration
Study NCT03947229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel mono-therapy
Description: Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
Study NCT03947229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual-antiplatelet therapy
Description: Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
Study NCT02863198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial injury
Description: Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
Study NCT01483677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Description: Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
Study NCT01483677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playstation 2
Description: Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
Study NCT03058744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion
Study NCT03058744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP Monad Lotion
Description: Lotion
Study NCT00266474 — intervention group
Intervention type: OTHER
Intervention: Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.
Study NCT03058744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream
Study NCT03058744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream
Study NCT02942264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02)
Description: Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.
Study NCT01832415 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Observation of bevacizumab administration in first line ovarian cancer treatment
Study NCT02942264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.
Study NCT02406261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: 50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
Study NCT02406261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg simvastatin will be administered orally as 1 × 20-mg tablet
Study NCT02406261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
Study NCT02942264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.
Study NCT02313688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
Study NCT02313688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
Study NCT04807959 — intervention group
Intervention type: OTHER
Intervention: 20Lighter anti-obesity program
Description: A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
Study NCT00926926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Gel
Description: Once daily for 7 days, followed by single dose of acetaminophen
Study NCT00926926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Once daily for 7 days, followed by single dose of acetaminophen
Study NCT01696461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT01943656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobii™ Eyegaze System
Description: Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
Study NCT01714466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Study NCT01714466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NER1006
Study NCT01714466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVIPREP
Study NCT01714466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Study NCT04166552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken once a day
Study NCT04166552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to receive EHP-101 or Placebo
Description: EHP-101 or placebo will be taken twice a day
Study NCT04447547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study NCT04143633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
Study NCT04143633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
Study NCT04143633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
Study NCT04143633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
Study NCT00902837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone naloxone prolonged release tablets (OXN)
Study NCT00902837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone prolonged release tablet
Study NCT02792426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Research ENDS S-TA-U001
Study NCT02792426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Inhalator
Study NCT00938106 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: optimised magnetic resonance image-guided intra-uterine brachytherapy
Description: Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
Study NCT04511507 — intervention group
Intervention type: PROCEDURE
Intervention: hemoadsorption
Description: three consecutive sessions of hemoadsorption in patients with liver failure
Study NCT03079765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral skills training
Description: Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
Study NCT03079765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol Only
Description: Participants will be given a written protocol describing how to conduct the target assessment procedure.
Study NCT03079765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protocol Only
Description: Participants will be given a written protocol describing how to conduct the target assessment procedure.
Study NCT02776878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT04383431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Description: Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.
Study NCT00902837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone naloxone tablet
Study NCT01645839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cytarabine
Description: 50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
Study NCT01328093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2140023
Description: Administered orally
Study NCT01328093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT01328093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administered orally
Study NCT03570905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Tong Splint
Description: A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
Study NCT00977652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active stimulation
Description: percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
Study NCT00977652 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Same location with the same device than active stimulation but amplitude of stimulation = 0
Study NCT03570905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clam Shell Splint
Description: A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
Study NCT04032340 — intervention group
Intervention type: OTHER
Intervention: dog presence
Description: This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
Study NCT01322815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy and GI-4000
Description: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks
Study NCT01322815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
Study NCT01113424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
Study NCT01113424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette® (Nicotine Gum)
Description: Single-dose of marketed nicotine gum 2 mg or 4 mg